CU20090007A6 - A PHARMACEUTICAL COMPOUND AND A PROCESS OF THE SAME - Google Patents

A PHARMACEUTICAL COMPOUND AND A PROCESS OF THE SAME

Info

Publication number
CU20090007A6
CU20090007A6 CU20090007A CU20090007A CU20090007A6 CU 20090007 A6 CU20090007 A6 CU 20090007A6 CU 20090007 A CU20090007 A CU 20090007A CU 20090007 A CU20090007 A CU 20090007A CU 20090007 A6 CU20090007 A6 CU 20090007A6
Authority
CU
Cuba
Prior art keywords
pharmaceutically acceptable
immunosuppressant
same
pharmaceutical compound
egfr
Prior art date
Application number
CU20090007A
Other languages
Spanish (es)
Other versions
CU23798B6 (en
Inventor
Venkata Chivukula Indira
Nair Pradip
Melarkode Ramakrishnan
Casimiro Jose Enrique Montero
Rodriguez Rolando Perez
Original Assignee
Biocon Ltd
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Centro Inmunologia Molecular filed Critical Biocon Ltd
Publication of CU20090007A6 publication Critical patent/CU20090007A6/en
Publication of CU23798B6 publication Critical patent/CU23798B6/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona una combinación terapéutica de un agente inhibidor del EGFR que inhibe competitivamente la unión del EGF nativo a su receptor y un inmunosupresor para tratar un huésped mamífero, preferiblemente humano mediante la administración de una cantidad terapéuticamente efectiva del fármaco para la profilaxis y/o tratamiento de tumores. El Inmunosupresor seleccionado del grupo comprende la Rapamicina, el tacrolimus, everolimus, pimecrolimus en su forma libre o en la forma de una sal o solvatos farmecéuticamente aceptables. También se comtemplan los nuevos conjugados del anti-EGFR con fármacos, y las composiciones que contengan opcionalmente por lo menos un portador farmacéuticamente aceptable para uso simultáneo.A therapeutic combination of an EGFR inhibitor is provided that competitively inhibits the binding of native EGF to its receptor and an immunosuppressant to treat a mammalian host, preferably human by administering a therapeutically effective amount of the drug for prophylaxis and / or treatment. of tumors The immunosuppressant selected from the group comprises Rapamycin, tacrolimus, everolimus, pimecrolimus in its free form or in the form of a pharmaceutically acceptable salt or solvate. The new anti-EGFR conjugates are also contemplated with drugs, and compositions that optionally contain at least one pharmaceutically acceptable carrier for simultaneous use.

CU20090007A 2007-10-22 2009-01-13 PHARMACEUTICAL COMBINATION USING ANTIBODIES AGAINST THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND IMMUNOSUPPRESSING AGENTS CU23798B6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2373CH2007 2007-10-22

Publications (2)

Publication Number Publication Date
CU20090007A6 true CU20090007A6 (en) 2011-07-11
CU23798B6 CU23798B6 (en) 2012-03-15

Family

ID=40579132

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090007A CU23798B6 (en) 2007-10-22 2009-01-13 PHARMACEUTICAL COMBINATION USING ANTIBODIES AGAINST THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND IMMUNOSUPPRESSING AGENTS

Country Status (5)

Country Link
AR (1) AR072759A1 (en)
CU (1) CU23798B6 (en)
TW (1) TW200942260A (en)
UY (1) UY31417A1 (en)
WO (1) WO2009054001A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
WO2020018291A1 (en) 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP4547911B2 (en) * 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド Phosphorus-containing compounds and uses thereof
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
KR20120064120A (en) * 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
JP2009514870A (en) * 2005-11-04 2009-04-09 ワイス Anti-neoplastic combinations of mTOR inhibitors, Herceptin, and / or HKI-272
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors

Also Published As

Publication number Publication date
WO2009054001A1 (en) 2009-04-30
CU23798B6 (en) 2012-03-15
TW200942260A (en) 2009-10-16
UY31417A1 (en) 2009-05-29
AR072759A1 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
CU20090007A6 (en) A PHARMACEUTICAL COMPOUND AND A PROCESS OF THE SAME
CO6390066A2 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AR048502A1 (en) ANTI-CANCER COMPOUND THERAPEUTIC SYNERGY
CO6251364A2 (en) DERIVATIVES OF MORFOLINO PIRIMIDINA USED IN DISEASES RELATED TO MTOR QUINASA AND / OR P13K
UY30559A1 (en) DERIVATIVES OF MORFOLINO PIRIMIDINA, PREPARATION PROCESSES, COMPOSITIONS CONTAINING THEM AND APPLICATIONS
UY29087A1 (en) ADAMANTILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USE
AR070299A1 (en) DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLININE DEPENDENT KINASES, USES AND PHARMACEUTICAL COMPOSITIONS
AR072442A1 (en) METHOD FOR CANCER THERAPY, USE, KIT
AR083787A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A SODIUM-GLUCOSE TRANSPORTER 2 INHIBITOR (SGLT2) AND AN INSULIN, TREATMENT PROCEDURES AND USES OF THE SAME
AR107871A1 (en) COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
EA200971081A1 (en) PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7
ECSP109934A (en) COMPOUND - 946
AR085183A1 (en) COMPOUND 6- (1-METHYL-1H-PIRAZOL-4-IL) -3- (2-METHYL-2H-INDAZOL-5-ILTIO) - [1,2,4] TRIAZOL [4,3-B] PIRIDAZINE, PHARMACEUTICAL COMPOSITION THAT UNDERSTAND AND USE IT TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT CANCER
AR059982A1 (en) TUMOR THERAPY WITH AN ANTIBODY AGAINST THE VASCULAR ENDOTELIAL GROWTH FACTOR AND AN ANTIBODY AGAINST THE HUMAN TYPE 2 EPITELIAL GROWTH FACTOR RECEIVER
EA200901155A1 (en) MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTIC PREPARATIONS (OPTIONS) AND THEIR USE IN THERAPY
AR063096A1 (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASE
AR079256A1 (en) METHOD FOR THE TREATMENT OF METASTASIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
UY31672A1 (en) "MUSCARINIC RECEPTORS AGONISTS PHARMACEUTICAL COMPOSITIONS METHODS OF TREATMENT OF THE SAME, AND PROCEDURES FOR THEIR PREPARATION"
CY1114163T1 (en) METHODS OF USE OF ANGIOPYCIN COMPETITORS WITH CARBON CYCLOTHERIC AGENTS TO REDUCE CARDIOTOXICITY AND / OR IMPROVEMENT
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
MX2021006012A (en) 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE.
AR059501A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
ECSP19026973A (en) NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
AR083267A1 (en) PHARMACEUTICAL COMBINATIONS

Legal Events

Date Code Title Description
FG Grant of patent